Moderna’s cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled
Summary
Moderna shares fell following an apparent leak of information regarding an experimental cancer vaccine. The company and Merck plan to present the full Phase 3 trial results at an upcoming medical conference this weekend.
A ‘sell-the-news reaction’? The experimental treatment helped prevent the return of cancer or death in melanoma patients by 42% after two years.
Source: Read the full story at MarketWatch.com - Top Stories
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.